Metabolic and inflammatory parameters changes in schizophrenic patients during three months of treatment with long acting risperidone

被引：0
|
作者：
Karlovic, D. [1 ]
Solter, V. [1 ]
Potkonjak, J. [1 ]
机构：
[1] Univ Zagreb, Sestre Milosrdnice Univ Hosp, Dept Psychiat, Zagreb, Croatia
来源：
EUROPEAN PSYCHIATRY | 2007年 / 22卷
关键词：
D O I：
10.1016/j.eurpsy.2007.01.509
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：S157 / S157
页数：1
相关论文
共 50 条
  • [1] Weight gain and hyperprolactinemia in schizophrenic patients treated during twelve months with long acting risperidone
    Duval, Fabrice
    Garcia, Frederico Duarte
    Lopera, Felix Gonzales
    Mokrani, Marie-Claude
    Hode, Yann
    Fattah, Said
    Diep, Than Son
    BIOLOGICAL PSYCHIATRY, 2008, 63 (07) : 284S - 284S
  • [2] WEIGHT GAIN AND HYPERPROLACTINEMIA IN SCHIZOPHRENIC PATIENTS TREATED DURING TWELVE MONTHS WITH LONG ACTING RISPERIDONE
    Garcia, F. Duarte
    Duval, F.
    Lopera, F. Gonzales
    Mokrani, M. -C.
    Hode, Y.
    Fattah, S.
    Diep, T. Son
    EUROPEAN PSYCHIATRY, 2009, 24
  • [3] Treatment of schizophrenic patients - Recurrence rate falls with long-acting risperidone
    Oetzel, S
    NERVENHEILKUNDE, 2004, 23 (08) : 87 - 87
  • [4] Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients
    Lucia Sara Volonteri
    Giancarlo Cerveri
    Ilaria Francesca De Gaspari
    Maria Luisa Baldi
    Maria Laura Rolandi
    Pietro Papa
    Massimo Carlo Mauri
    Claudio Mencacci
    Psychopharmacology, 2010, 210 : 489 - 497
  • [5] Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients
    Volonteri, Lucia Sara
    Cerveri, Giancarlo
    De Gaspari, Ilaria Francesca
    Baldi, Maria Luisa
    Rolandi, Maria Laura
    Papa, Pietro
    Mauri, Massimo Carlo
    Mencacci, Claudio
    PSYCHOPHARMACOLOGY, 2010, 210 (04) : 489 - 497
  • [6] Changes in auditory gating and clinical scores in schizophrenic patients during risperidone treatment
    Kishimoto, T
    Harada, Y
    Kobayashi, M
    Segawa, Y
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 : S14 - S15
  • [7] Prolactin response to oral and long-acting forms of risperidone in schizophrenic patients
    Duval, Fabrice
    Chokmani, Nessim
    Mokrani, Marie-Claude
    He, Jun
    Duarte-Garcia, Frederico
    Macher, Jean-Paul
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 83S - 83S
  • [8] Prolactin response to oral and long-acting forms of risperidone in schizophrenic patients
    Duval, F.
    Chokmani, N.
    Mokrani, M. C.
    He, J.
    Macher, J. P.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S440 - S440
  • [9] Efficacy and safety of long-acting risperidone in schizophrenic stable subjects durring 6 months period
    Gugleta, D. G.
    Slaykovic, Vs.
    Golubovic, S. T. G. Tosic
    Sibinovic, V. S.
    Stankovic, S. D.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S496 - S496
  • [10] EFFECTIVENESS OF LONG-ACTING INJECTABLE RISPERIDONE IN THE POST-ACUTE TREATMENT OF SCHIZOPHRENIC PATIENTS IN AMBULATORY CARE
    Hargarter, L.
    Diekamp, B.
    Ibach, B.
    Juckel, G.
    EUROPEAN PSYCHIATRY, 2010, 25
12345